ArticleClinical nuclear medicine2020
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up.
Article in Clinical nuclear medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Diagnostic impact of 18F-FDG PET/MRI over PET/CT in histiocytoses: a prospective comparative study.European journal of nuclear medicine and molecular imaging · 2026Article
- A Rare Case of Rosai-Dorfman Disease Involving Great Vessels of the Heart Mimicking Breast Cancer Recurrence.Annals of thoracic surgery short reports · 2026Article
- Rosai-Dorfman disease in the breast: a case report and literature review.Frontiers in oncology · 2026Review
- Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.Hematology. American Society of Hematology. Education Program · 2025Review
- Sinonasal presentations of Rosai-Dorfman disease: a scoping review.The Journal of laryngology and otology · 2025Review
- Extensive Multiorgan and Neurological Involvement on F-18 FDG PET-CT in a Case of Rosai-Dorfman Disease.World journal of nuclear medicine · 2024Article
- Rosai-Dorfman-Destombes disease in adults: a single center experience.Annals of hematology · 2024Article
- Fourth Ventricular Rosai-Dorfman Disease Mimicking Intraventricular Tumor in Young Adult: A Rare Case Report.Asian journal of neurosurgery · 2024Article
- Characterizing Rosai-Dorfman disease with [European radiology · 2023Article
- Rare Extranodal Manifestation of Rosai-Dorfman Disease Presenting as Nasal Obstruction and its Management.BMJ case reports · 2023Article
- Extranodal Rosai-Dorfman disease involving pulmonary artery detected byEuropean journal of nuclear medicine and molecular imaging · 2023Article
- The value ofOrphanet journal of rare diseases · 2023Review
- Rosai-Dorfman disease of the breast: the breast cancer mimic.BMJ case reports · 2023Article
- The Impact of PET/CT on Paediatric Oncology.Diagnostics (Basel, Switzerland) · 2023Review
- Unusual sites of Rosai-Dorfman disease in children: 5 years experience from tertiary care paediatric haemato-oncology centre.Sudanese journal of paediatrics · 2022Article
- Potential role ofAsia Oceania journal of nuclear medicine & biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe role of imaging in the management of Rosai-Dorfman disease (RDD), a rare non-Langerhans cell histiocytosis, is not clearly defined. We present an analysis of FDG PET/CT findings obtained for initial disease characterization, follow-up evaluation, and treatment planning for this disease.
methodsFrom an institutional pathology database (2001-2018), we identified RDD patients who underwent FDG PET/CT scans either as part of clinical care or when done as part of clinical trials. For all scans, sites of abnormal FDG uptake were assessed, and SUVmax was measured. Comparison of PET/CT findings was made with anatomic (CT/MRI-based) imaging, where available. Instances of changing treatment based on PET/CT were recorded.
resultsWe reviewed 109 FDG PET/CT scans in 27 patients with RDD. Five of 27 patients had only nodal/cutaneous disease, whereas 22 patients had extranodal disease, most commonly in bone (n = 9) and central nervous system (n = 7). PET/CT identified sites of active disease in 24 of 27 patients. All identified bone and extraskeletal lesions, except for a brain lesion in 1 patient, were FDG-avid. In 6 of 20 patients (30%) with available prior CT or MRI, PET/CT demonstrated additional RDD lesions (bones: n = 5, pleura: n = 1) that were not apparent on anatomic imaging; 3 of these lesions were outside the CT field of view, and 3 were not recognized on CT. Overall, 13 of 109 PET/CT scans led to a change in management, affecting 41% (11/27) of patients.
conclusionFDG PET/CT was valuable in defining disease extent and optimizing treatment strategy in patients with RDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.